Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New weekly shot could help chinese adults shed pounds and control diabetes

NCT ID NCT07670416

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 6 times

Summary

This phase 3 trial is testing a once-weekly injection called enicepatide in 300 Chinese adults who are obese or overweight, with or without type 2 diabetes. The drug works by mimicking two gut hormones to reduce appetite and improve blood sugar control. Participants will receive either the drug or a placebo, along with diet and exercise advice, for 52 weeks to see how much weight they lose.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Enicepatide (a weekly injection that targets two gut hormones to reduce appetite and improve blood sugar)
What this could lead to
If successful, this could offer a new once-weekly injection to help Chinese adults with obesity or overweight lose significant weight and manage type 2 diabetes.
What could go wrong
This is a phase 3 trial, but results may not apply to other populations. Side effects like nausea or vomiting are common with this drug class, and long-term safety is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 300 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) ≥24.0 kilograms per meter squared (kg/m\^2) for participants with type 2 diabetes mellitus (T2DM) * BMI ≥28.0 kg/m\^2 or BMI ≥24.0 and \<28.0 kg/m\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM * Agreement to adhere to the contraception requirements Exclusion Criteria: * History of Type 1 diabetes mellitus (T1DM) * Obesity induced by other endocrinologic disorders * Any planned major medical procedure or surgery during the study * History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder * Any lifetime history of suicide attempt * History of any hematologic conditions that may interfere with HbA1c measurement * History of acute or chronic pancreatitis or clinically significant gallbladder disease * Treatment with any approved or investigational GLP-1-RA-based therapy within 6 months prior to randomization * Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer * Known allergy to any component of the study drug formulation or any other condition that is a contraindication to GLP-1 RAs or GLP-1/GIP RAs

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity Overweight Type 2 diabetes mellitus (T2DM)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    21 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hebei Medical University - The Second Hospital

    RECRUITING

    Shijiazhuang, 050004, China

  • Hebei Petro China Central Hospital

    RECRUITING

    Langfang, 065000, China

  • Huai'an First People's Hospital

    RECRUITING

    Huai'an, China

  • Huzhou Central Hospital

    RECRUITING

    Huzhou, 313000, China

  • Jinan Central Hospital

    RECRUITING

    Jinan, 250013, China

  • Luoyang Third People's Hospital

    RECRUITING

    Luoyang, 471000, China

  • Peking University People's Hospital

    RECRUITING

    Beijing, 100044, China

  • Shanghai East Hospital

    RECRUITING

    Shanghai, 200120, China

  • Shanghai Fifth People's Hospital Affiliated to Fudan University

    RECRUITING

    Shanghai, 201304, China

  • Shanghai Tenth People's Hospital

    RECRUITING

    Shanghai, 200072, China

  • Shenyang Fifth People Hospital

    RECRUITING

    Shenyang, 110074, China

  • The Affiliated Jiangning Hospital of Nanjing Medical University

    RECRUITING

    Nanjing, 211100, China

  • The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)

    RECRUITING

    Ningbo, Zhejiang, 315010, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    RECRUITING

    Herbin, 150001, China

  • The People's Hospital of Liaoning Province

    RECRUITING

    Shenyang, 110016, China

  • The Second Affiliated Hospital of Anhui Medical University

    RECRUITING

    Hefei, 230601, China

  • The Second Affiliated Hospital of Zhengzhou University

    RECRUITING

    Zhengzhou, Henan, 450014, China

  • The Second Hospital of Jilin University

    RECRUITING

    Changchun, 130041, China

  • Tongren Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, 200336, China

  • Yan'an University Xianyang Hospital

    RECRUITING

    Xianyang, Shaanxi, 712000, China

  • Zibo Municipal Hospital.

    RECRUITING

    Zibo, 255400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.